Enrolling Studies
Contact a Hope Clinic study recruiter
COVID-19 Studies
Observational Study of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults
RECOVER researchers are studying Long COVID and other types of PASC (post-acute sequelae of SARS-CoV-2 infection). PASC is the name for all the long-term health effects that people may have after getting COVID.
Basic Qualifications:
- Ages 18+
- Tested positive for COVID in the last 30 days
ACTIV-6 is testing medications that are already approved for other diseases to learn if they can help people with mild-to-moderate COVID-19 feel better faster and stay out of the hospital.
Basic Qualifications:
- Adults aged 30+
- Tested positive for COVID-19 in the past 10 days
- Have at least 2 COVID-19 symptoms
To participate or for more information please contact Cecilia Zhang at (404) 638-5028 or email cecilia.xi.zhang@emory.edu
More Information on COVID-19 Studies
Vaccine and Treatment Evaluation Unit (VTEU) - Non-COVID Studies
DMID 19-0015
The purpose of this study is to test the Bexsero meningitis vaccine against the gonorrhea infection.
Basic Qualifications:
- Healthy adults (Ages 18-49)
- No history of gonorrhea or meningitis infection
- Never had a meningococcal group B vaccine
To participate or for more information, please call Brittany Robinson at 404-710-4007 or send an email to vaccine@emory.edu
HIV Vaccine Trials Network
The purpose of this study is to evaluate the safety and tolerability of an experimental HIV vaccine. We are looking for healthy volunteers between the ages of 18 and 50. The study will involve 12 to 25 clinic visits spread out over 12 to 25 months and include several study procedures.
To participate or for more information, please contact Rameses Frederick at rameses.frederick@emory.edu
OR
The purpose of this study is to evaluate the safety and immune responses of two experimental HIV vaccines. The vaccines include a protein mixed with something called an adjuvant, which gives your immune response an extra boost. We are looking for healthy volunteers between the ages of 18 and 55. Participants will receive the study vaccine three times (at months 0, 2 and 6). The study involves a total of 13 visits over 18 months. We may collect blood or urine samples at study visits and will have you fill out a diary of how the vaccine makes you feel.
To participate or for more information, please contact Rameses Frederick at rameses.frederick@emory.edu
OR
Sexual Health Studies
To participate or for more information about the following studies, please email us at hope.community@emory.edu or call at 877-288-0048
The CFAR Repository Study aims to store a library of samples so they are available for researchers who need them. This study is looking for HIV-negative people of any gender to participate.
The purpose of this study is to collect blood and rectal biopsy specimens from HIV infected individuals, HIV negative at-risk individuals, or HIV negative low-risk individuals to better understand HIV transmission and/or disease.
The purpose of this study is to learn more about how immune system responses in the rectum change when people take sex hormones, like estrogen and testosterone. The researchers conducting this study think that when a transgender person (someone whose gender does not match their assigned sex at birth) takes sex hormones to affirm their gender identity, this could change how their immune system responds and may increase their risk of getting infection with HIV. These changes to the immune system could also impact how well the body responds to an HIV vaccine in the future. This study will consist of 42 healthy, HIV-negative individuals (21 individuals assigned male sex at birth and 21 individuals assigned female sex at birth), aged 18-39 who do not use any hormonal treatments. Participants will undergo body site sampling, including blood and rectal sampling.
This study will test the experimental drug Lenacapavir (LEN) for the prevention of HIV infection, also known as Pre-Exposure Prophylaxis (PrEP). This study will also compare the effectiveness of LEN to Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF; Truvada®), which has already been approved in several countries for use as PrEP. Participants will recieve a HIV test. Once the results are negative, they can then be enrolled in the study. Purpose 2 is open to the trans women, trans men, gender non-conforming individuals, men who have sex with men.
The TRANSExplore Study aims to better understand the effect of feminizing hormones on the tissues that line the rectum. Transgender women, as well as cisgender men, will be eligible to participate.
Investigator Initiated, Observational, and Other Studies
Shingrix VAX2-007
This study is being done to investigate the response of the immune system to the herpes zoster (shingles) vaccine.
Basic Qualifications:
- Healthy adults (Ages 70+)
- Cannot have received Shingles vaccine
- Cannot have had Shingles infection
To participate or for more information, please call Eileen Osinski at 404-712-1371 or send an email to gosinsk@emory.edu
A clinical trial research study investigating the yellow fever vaccine. Adults who have never had the yellow fever vaccine but are planning on getting the vaccine may be eligible to participate in the study. Participants need to be between the ages of 18-45 years of age, in generally good health and must have never received the yellow fever vaccine before. Volunteers will be compensated for all study visits. Compensation is $75 for a screening appointment and $75 for each follow-up appointment (3-7 visits).
To participate or for more information, please email vaccine@emory.edu or call 404-712-1371.
This study examines how the immune system responds to the flu virus (H3N2) during and after infection and how the flu virus is transmitted in the environment.
Basic Qualifications:
- Healthy adults (Ages 18-49)
- Willing to receive an influenza challenge
- Inpatient hospital stay required (10 days)
To participate or for more information, please email Alexandra Koumanelis at akouman@emory.edu.
This study is being conducted to understand how the Gardasil 9 HPV vaccine generates high levels of long-lasting antibodies in humans.
Basic Qualifications:
- Healthy adults (Ages 18-45)
- No history of HPV or HPV vaccine
To participate or for more information, please email Lana Khalil at lana.khalil@emory.edu.
The purpose of the study is to better understand how the body’s immune system responds to two types
of vaccines, yellow fever vaccine and the influenza vaccine which are currently approved in the USA, over
a period of time. This will help us understand the differences in the responses to the two different types
of vaccines and will help to create better long-lasting vaccines in the future.
Basic Qualifications:
- Healthy adults (Ages 18-50)
- Willing to receive either FDA-approved Yellow Fever or Flu vaccine
To participate or for more information, please email Bahaa Kazzi at bahaa.kazzi@emory.edu.
This study is being conducted to understand the effects of hormonal therapy on immunological response in transgender adults 18+.
To participate or for more information, please email Ghina Alaaeddine at ghina.alaaeddine@emory.edu.
Monetary compensation for time and travel varies depending on the study